Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-24 @ 11:49 PM
NCT ID:
NCT00499551
Eligibility Criteria:
Inclusion Criteria:
* Clinical history of, none-infectious anterior, intermediate, posterior or panuveitis, with or without associate systemic disease, like: Vogt Koyanagi Harada, Wegener Granulomatosis, Systemic erythematous Lupus, Behçet disease, etc.
* Requirement or with current topical treatment with steroids (more than every 6 hours), needs acute or chronic treatment with oral, intravenous, periocular or intravitreous corticosteroids or immunosuppressive agents for the control of the disease.
* Best Corrected Visual Acuity in the worse eye of 20/40 to 20/800 in ETDRS record.
* Patients with good mydriasis and no significant ocular opacities.
* Patients who do not plan elective surgery.
Exclusion Criteria:
* Infectious, pos-traumatic, Fuchs or self-limited uveitis. Patients with Diagnosis of glaucoma or ocular hypertension (greater than 25mmHg).
* Diagnosis or suspects ocular or central nervous system lymphoma. Patients with only one eye.
* Associated optical Neuritis of any etiology.
* Severe injuries in the eyelids or in the ocular surface that prevent the application of the electrode.
* Well-known allergy to the Dexamethasone.
* Toxoplasma scar or vitreous hemorrhage.
* Corneal injuries of herpetic origin or with suspicion of being herpetic.
* Patients with poor mydriasis, significant ocular opacities that prevents the evaluation of the posterior pole or the follow-up studies.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Maximum Age:
90 Years
Study:
NCT00499551
Study Brief:
Protocol Section:
NCT00499551